Melanoma

Case Report of a KIT-mutated Melanoma Patient With an Excellent Response to Apatinib and Temozolomide Combination Therapy

Case Report of a KIT-mutated Melanoma Patient With an Excellent Response to Apatinib and Temozolomide Combination Therapy

[OncoTargets and Therapy] This article examines a case of metastatic melanoma in which the patient had an excellent response to apatinib/TMZ combination therapy with progression-free survival for more than one year.

Overall Survival Increase for Melanoma Brain Metastases

Overall Survival Increase for Melanoma Brain Metastases

Median overall survival from time of diagnosis has increased from 7.5 to 22.7 months

Overall Survival in Advanced Melanoma Improved With Nivolumab, Ipilimumab Combination

Overall Survival in Advanced Melanoma Improved With Nivolumab, Ipilimumab Combination

By

Overall survival was significantly prolonged in patients with advanced melanoma who were treated with nivolumab plus ipilimumab compared with either drug alone, according to results from the Checkmate 067 study.

Risk of Some Cancers Higher in Women With a History of Periodontal Disease

Risk of Some Cancers Higher in Women With a History of Periodontal Disease

By

A study on a cohort of women enrolled in the WHI-OS shows that those with a history of periodontal disease had a higher risk for developing some cancers.

Awareness of Genomic Risk for Melanoma May Increase Conversations With Family, Health Care Providers

Awareness of Genomic Risk for Melanoma May Increase Conversations With Family, Health Care Providers

By

Awareness of personal genetic risk for melanoma may prompt patients to discuss cancer risk with family and health care professionals, and make lifestyle changes.

FDA Expands Ipilimumab Indication to Include Pediatric Unresectable or Metastatic Melanoma

FDA Expands Ipilimumab Indication to Include Pediatric Unresectable or Metastatic Melanoma

By

The FDA approved the indication expansion for ipilimumab based on evidence from 2 clinical trials evaluating its safety and efficacy in pediatric patients.

Melanoma Diagnoses Can Vary Widely Among Pathologists

Melanoma Diagnoses Can Vary Widely Among Pathologists

When researchers sent sample slides to pathologists for review, the assessments varied widely and some pathologists even disagreed with their own initial assessment when retested months later.

Adjuvant Bevacizumab Does Not Increase Survival in High-Risk Melanoma

Adjuvant Bevacizumab Does Not Increase Survival in High-Risk Melanoma

By

Five-year survival rate found similar to observation despite a significant improvement in disease-free interval.

Higher-Dose Adjuvant Ipilimumab More Toxic, Does Not Improve Recurrence-Free Survival

Higher-Dose Adjuvant Ipilimumab More Toxic, Does Not Improve Recurrence-Free Survival

By

Study of patients with resected high-risk melanoma reveals higher rates of treatment-related adverse events with 10 vs 3 mg/kg.

Cancer Recurrence Fear Reduced by Novel Psychological Intervention

Cancer Recurrence Fear Reduced by Novel Psychological Intervention

By

'Conquer Fear' decreased fear among survivors of breast and colorectal cancer and melanoma compared with relaxation techniques.

Biopolymer Delivery of Synergistic Immunotherapy Could Improve Efficacy

Biopolymer Delivery of Synergistic Immunotherapy Could Improve Efficacy

By

Biopolymer codelivery of CAR T cells and stimulator of IFN genes directly to the surface of solid tumors more effectively reduced tumor size.

Noninvasive 2-Gene Test Helps Distinguish Melanoma From Nonmelanoma

Noninvasive 2-Gene Test Helps Distinguish Melanoma From Nonmelanoma

By

Two-gene pigmented lesion test classifies skin lesions as melanoma or nonmelanoma, helping with diagnostic challenges faced with the visual image and pattern recognition approach.

Assessment of Melanoma Screening Practices Produces Data-Driven, Risk-Based Guidelines

Assessment of Melanoma Screening Practices Produces Data-Driven, Risk-Based Guidelines

By

Dermatologist assessment of screening practices addresses the lack of a national consensus on screening guidelines for melanoma.

Psoriasis May Increase Risk of Melanoma and Hematologic Cancers

Psoriasis May Increase Risk of Melanoma and Hematologic Cancers

Patients with psoriasis had 1.53 times greater risk of developing a malignancy, regardless of the type of psoriasis therapy they are receiving.

Genome Sequencing Explains Resistance to CTLA-4 and PD-1 Inhibitors in Metastatic Melanoma

Genome Sequencing Explains Resistance to CTLA-4 and PD-1 Inhibitors in Metastatic Melanoma

By

Whole-exome sequencing of tumor biopsies explain low response rate to immunotherapy in metastatic melanoma.

Kinase Inhibitors: Managing Adverse Effects in the Treatment of Metastatic Melanoma

Kinase Inhibitors: Managing Adverse Effects in the Treatment of Metastatic Melanoma

By

Despite their efficacy in metastatic melanoma, KIs include risk of serious side effects in patients. This overview explains the effects and management recommendations for 4 agents used to treat metastatic melanoma.

Dabrafenib + Trametinib Rechallenge Active in Pretreated Melanoma

Dabrafenib + Trametinib Rechallenge Active in Pretreated Melanoma

By

Rechallenge with dabrafenib plus trametinib demonstrated antitumor activity in patients who had previously progressed on BRAF inhibitor therapy.

Antidiabetes Drug Holds Promise as Adjuvant Therapy for Older Patients with Melanoma

Antidiabetes Drug Holds Promise as Adjuvant Therapy for Older Patients with Melanoma

By

Rosiglitazone has potential for older patients with melanoma who develop resistance to targeted therapies.

Cost-Effectiveness of Immunotherapy for Advanced Melanoma Evaluated

Cost-Effectiveness of Immunotherapy for Advanced Melanoma Evaluated

By

Researchers sought to conduct a cost-effectiveness analysis of immunotherapy for patients with advanced melanoma.

Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer

Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer

By

Clinical trials show pembrolizumab active against mucosal melanoma, extends survival in bladder cancer.

Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline

Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline

By

Using statistical models, predictions were made for death rates from melanoma in 3 three countries and based on availability of a treatment.

Computer 'Deep Learning' Algorithm Matches Dermatologists at Classifying Melanomas

Computer 'Deep Learning' Algorithm Matches Dermatologists at Classifying Melanomas

By

Researchers compared the ability of an artificial-intelligence algorithm to recognize and classify skin cancers with the clinical evaluations of dermatologists.

IFN Induction No Better Than Observation for Intermediate-risk Melanoma

IFN Induction No Better Than Observation for Intermediate-risk Melanoma

By

Induction therapy with intravenous interferon α-2b appeared to be no better than observation alone for the management of patients with intermediate-risk melanoma.

Customers Find Useful Information in Results from Direct-to-Consumer Genetic Testing

Customers Find Useful Information in Results from Direct-to-Consumer Genetic Testing

By

Results of a series of Internet surveys revealed customers' perceptions of harms, benefits, and limitations of genetic information received from direct-to-consumer genetic testing.

Beach Umbrella Not Enough for Protection from UV Rays

Beach Umbrella Not Enough for Protection from UV Rays

By

Comparison studied the effectiveness of sun protection offered by a beach umbrella alone with that of sunscreen with a high sun protection factor.

Melanoma Incidence Still on the Rise in Parts of the United States

Melanoma Incidence Still on the Rise in Parts of the United States

Melanoma incidence varies by region, and many states have experienced an increase.

Alcohol Consumption, Particularly White Wine, Associated With Increased Risk of Melanoma

Alcohol Consumption, Particularly White Wine, Associated With Increased Risk of Melanoma

By

A review of data from three large, prospective studies examined a potential association between alcoholic beverage consumption and risk of melanoma.

Study Identifies Factors Associated With Outcomes After Dabrafenib + Trametinib

By

Despite the effectiveness of dabrafenib in combination with trametinib for metastatic BRAF-mutant melanoma, many patients experience disease progression that often leads to death. In this data analysis, researcher sought to identify clinical factors associated with long-term response and survival.

PD-1 Inhibitors Ideal for First-Line Therapy in Treatment-Naïve Advanced Melanoma

PD-1 Inhibitors Ideal for First-Line Therapy in Treatment-Naïve Advanced Melanoma

By

Atlhough survival for patients with advanced melanoma is similar with both targeted therapies and immunotherapies, a review of the literature reveals why one of them may be a better choice as first-line therapy.

Immune Checkpoint-Related Neurotoxicity May Be More Common During Combination Treatment

Immune Checkpoint-Related Neurotoxicity May Be More Common During Combination Treatment

By

Neurotoxicity is not uncommon in patients with melanoma treated with immune checkpoint inhibitors. In this study, therefore, researchers sought to examine the incidence of neurotoxicity across anti-CTLA-4 and anti-PD-1 antibodies at a single institution.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs